REDEFINE 1 Trial Finds CagrilintideSemaglutide Combo Delivers Over 20% Weight Loss in Majority of Patients Applied Clinical Trials Online New trial data on CagriSema 23% weight loss at 84 weeks in the RE DEFINE 4 trial. CagriSema pairs semaglutide with cagrilintide, an amylin analogue. Amylin is a pancreatic hormone that slows Cagrilintide Combined with Semaglutide: A New Approach for Treatment of Obesity and Type 2 Diabetes ClinicSearch Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Novo Nordisk's cagrilintide shows promise in Phase 3 trial Alan Nafiev posted on the topic LinkedIn